论文部分内容阅读
本文的目的是为探讨大肠癌ｂｃｌ—２／ｂａｘ基因产物表达与对化疗疗效的影响之间的关系。用免疫组化Ｓ—Ｐ技术检测２８例手术后随访５年以上的大肠癌标本中ｂｃｌ─２／ｂａｘ基因产物的表达。结果显示ｂｃｌ─２基因产物阳性表达者２３例，化疗后复发率５４．６％，５年生存率６９．５％。ｂｃｌ—２阴性表达者５例，复发率２５％，生存率８０％。ｂａｘ基因产物阳性表达者７例，复发率２０％，生存率８５．７％。ｂａｘ阴性表达者２１例，复发率５８．３％，生存率６６．７％。提示ｂｃｌ—２阳性表达对抗了化疗诱导的凋零，肿瘤复发率高于ｂｃｌ－２阴性者。ｂａｘ阳性表达促进了化疗诱导的凋零，肿瘤复发率低于ｂａｘ阴性者。监测ｂｃｌ—２／ｂａｘ表达有助于观察化疗疗效和预后。
The purpose of this paper is to investigate the relationship between the expression of bcl-2/bax gene product and the effect on chemotherapy efficacy in colorectal cancer. Immunohistochemical S-P technique was used to detect the expression of bcl-2/bax gene product in 28 colorectal cancer specimens that were followed for more than 5 years after operation. The results showed that there were 23 cases of positive expression of bcl-2 gene product, the recurrence rate after chemotherapy was 54.6%, and the 5-year survival rate was 69.5%. There were 5 cases with bcl-2 negative expression, the recurrence rate was 25%, and the survival rate was 80%. Bax gene product positive expression in 7 cases, the recurrence rate was 20%, the survival rate was 85.7%. Bax negative expression in 21 cases, the recurrence rate was 58.3%, and the survival rate was 66.7%. It was suggested that the positive expression of bcl-2 against chemotherapy-induced withering, tumor recurrence rate was higher than bcl-2 negative. The positive expression of bax promoted the chemotherapy-induced withering, and the tumor recurrence rate was lower than that of bax negative. Monitoring bcl-2/bax expression helps to observe the efficacy and prognosis of chemotherapy.